Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319


18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.

Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X.

J Nucl Med. 2006 Mar;47(3):492-501.


microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.

Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.

J Nucl Med. 2004 Aug;45(8):1390-7.


Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.


Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.

Yang YS, Zhang X, Xiong Z, Chen X.

Nucl Med Biol. 2006 Apr;33(3):371-80. Epub 2006 Mar 9.


GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.

Carlucci G, Kuipers A, Ananias HJ, de Paula Faria D, Dierckx RA, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH.

Peptides. 2015 May;67:45-54. doi: 10.1016/j.peptides.2015.03.004. Epub 2015 Mar 20.


18F-labeled BBN-RGD heterodimer for prostate cancer imaging.

Li ZB, Wu Z, Chen K, Ryu EK, Chen X.

J Nucl Med. 2008 Mar;49(3):453-61. doi: 10.2967/jnumed.107.048009. Epub 2008 Feb 20.


18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.

Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S.

J Nucl Med. 2011 Feb;52(2):270-8. doi: 10.2967/jnumed.110.081620. Epub 2011 Jan 13.


PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.

Dijkgraaf I, Franssen GM, McBride WJ, D'Souza CA, Laverman P, Smith CJ, Goldenberg DM, Oyen WJ, Boerman OC.

J Nucl Med. 2012 Jun;53(6):947-52. doi: 10.2967/jnumed.111.100891. Epub 2012 May 8.


A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.

Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, Yang M, Yan Y.

Amino Acids. 2014 Jun;46(6):1481-9. doi: 10.1007/s00726-014-1718-y. Epub 2014 Mar 17.


Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.


Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.

Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ.

Nucl Med Biol. 2003 Feb;30(2):101-9.


(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Liu Z, Yan Y, Liu S, Wang F, Chen X.

Bioconjug Chem. 2009 May 20;20(5):1016-25. doi: 10.1021/bc9000245.


In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.

Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.

J Nucl Med. 2011 Mar;52(3):470-7. doi: 10.2967/jnumed.110.082826. Epub 2011 Feb 14.


Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.

Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ.

Nucl Med Biol. 2008 May;35(4):401-11. doi: 10.1016/j.nucmedbio.2008.02.005.


A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.

Yan Y, Chen K, Yang M, Sun X, Liu S, Chen X.

Amino Acids. 2011 Jul;41(2):439-47. doi: 10.1007/s00726-010-0762-5. Epub 2010 Oct 10.


New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.

García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, Tourwé DA, Beck-Sickinger AG, Schubiger PA.

Q J Nucl Med Mol Imaging. 2007 Mar;51(1):42-50.


Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.

Ferro-Flores G, Arteaga de Murphy C, Rodriguez-Cortés J, Pedraza-López M, Ramírez-Iglesias MT.

Nucl Med Commun. 2006 Apr;27(4):371-6.


Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.

Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.

J Nucl Med. 2017 Jan;58(1):29-35. doi: 10.2967/jnumed.116.176099. Epub 2016 Aug 11.


Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.

Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.

J Nucl Med. 2017 Jan;58(1):75-80. doi: 10.2967/jnumed.116.178889. Epub 2016 Aug 4.


64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.

Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.

Nucl Med Biol. 2012 Apr;39(3):377-87. doi: 10.1016/j.nucmedbio.2011.10.004. Epub 2012 Jan 5.

Supplemental Content

Support Center